Clinical trial NCT03733990: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Official title: A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cancer
Lead sponsor: Faron Pharmaceuticals Ltd
Sponsor class: INDUSTRY
First posted: 2018-11-07
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Dose-escalation, six dose levels
Primary purpose: TREATMENT

Brief summary: This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity.

The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.


Eligibility criteria: Subjects must meet all of the following inclusion criteria to be eligible for participation in the clinical trial:

1. Written Informed Consent
2. Aged ≥ 18 years male or female
3. Tumour sample should be collected during screening period. If a recent tumour biopsy obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used. At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III
4. Life expectancy \> 12 weeks
5. Histologically confirmed advanced (inoperable or metastatic) malignancies without standard therapeutic options available:

   * Hepatocellular carcinoma
   * Gallbladder cancer or intra- or extrahepatic cholangiocarcinoma
   * Colorectal adenocarcinoma
   * Serous poorly differentiated (Grade 3) ovarian adenocarcinoma or undifferentiated ovarian cancer
   * Pancreatic ductal adenocarcinoma
   * Immunotherapy (IO) refractory cutaneous melanoma (progression either on or after programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy)
   * Uveal melanoma in Parts II and III
   * Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction) in Parts II and III
   * ER+ breast cancer in Parts II and III
   * Anaplastic thyroid cancer in Parts II and III
6. ECOG performance status 0 or 1
7. Measurable disease in Parts II and III
8. Adequate bone marrow, liver and kidney function defined as Blood white blood cell ≥ lower limit of normal Blood neutrophil count ≥ 1x10(9)/L Blood platelet count ≥ 100x10(9)/L, for HCC ≥ 50x10(9)/L Blood haemoglobin ≥ 9.0 g/dL Creatinine clearance \> 40 mL/min calculated by Cockcroft-Gault formula AST ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases are present) ALT ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases present) Bilirubin ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL The most recent measurements taken during the screening period must be within the required limits for the patient to be considered eligible (i.e. criteria met once during the screening period are not sufficient if there are more recent measurements available that are not within the required limits. It is however acceptable to repeat measurements if the initial measurements or subsequent measurements taken during the screening period are not within the required limits; the patient is eligible providing that the newest measurements are within the required limits). However, once a subject is out of the screening period, and has had eligibility confirmed and been enrolled, the pre-dose laboratory assessments are not subjected to inclusion criteria limits, but only for investigators assessment of subject safety.
9. Women of child-bearing potential must have a negative pregnancy test in serum prior to trial entry
10. Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment

Exclusion Criteria;

1. Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration
2. Any immunotherapy within preceding 6 weeks from the first IMP administration
3. Investigational therapy or major surgery within 4 weeks from the date of consent
4. Active clinically serious infection \> Grade 2 NCI-CTCAE version 5.0 (Appendix 5 - Common Toxicity Criteria Gradings) within preceding 2 weeks from the date of consent
5. Brain metastases
6. Subject has not recovered from the previous therapies to Grade ≤ 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade ≤ 2 alopecia, neuropathy or thyroid disorders)
7. Pregnant or lactating women
8. History of second malignancy except for non-melanotic skin cancer, cervical carcinoma in situ or superficial bladder cancer, or any other malignancy treated previously with curative intent and more than three years without relapse
9. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure New York Heart Association (NYHA) class 2 (Appendix 7 - NYHA classification), Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial
10. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment
11. Confirmed human immunodeficiency virus infection
12. Symptomatic cytomegalovirus infection
13. Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)
14. The subject requires systemic corticosteroid or other immunosuppressive treatment
15. Subjects with organ transplants
16. Subjects in dialysis
17. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit
18. Subject is unwilling or unable to comply with treatment and trial instructions
19. Subjects with known hypersensitivity to the IMP or any of the pharmaceutical ingredients

Specific Additional Exclusion Criteria for Hepatobiliary Cancers

1. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC (this should not exclude subjects if target lesion(s) have not been treated and occurred \> 6 weeks prior trial entry)
2. Hepatic encephalopathy
3. Ascites refractory to diuretic therapy
4. Child-Pugh score ≥ 7

Primary outcomes:
measure: Dose Limiting Toxicities (DLT) in the Trial Subjects.
timeFrame: Up to one year
measure: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
timeFrame: approximately 4 years and 9 months
measure: The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
timeFrame: approximately 4 years and 9 months
measure: The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
timeFrame: approximately 4 years and 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: The University of Texas Health Science Center at San Antonio
state: Texas
city: Helsinki
country: Finland
facility: Clinical Research Institute HUCH Ltd
city: Oulu
country: Finland
facility: Oulu University Hospital
city: Tampere
country: Finland
facility: Tampere University Hospital
city: Turku
country: Finland
facility: Turku University Hospital
city: Villejuif
country: France
facility: The Institut Gustave Roussy
city: Rotterdam
country: Netherlands
facility: Erasmus University Medical Center Rotterdam
city: Madrid
country: Spain
facility: START Madrid - CIOCC Hospital HM Sanchinarro
city: Sutton
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
state: Surrey
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital Birmingham
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
Study officials:
affiliation: Terveystalo Ltd
name: Petri Bono, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hollmen M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21(7):1207-1218. doi: 10.1158/1535-7163.MCT-21-0840.
citation: Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lonnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skytta T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmen M. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2.